We propose that dysregulated processing and expression of extracellular CDCP1 reflect the tumor microenvironment and a full structural characterizationis warranted to determine if circulating CDCP1 can provide a diagnostic/prognostic tool for management of prostate cancer. This evidence concerns the gene CDCP1 and Familial prostate cancer.